+

WO2002070679A3 - Peptide fragments, derived from human telomerase reverse transcriptase - Google Patents

Peptide fragments, derived from human telomerase reverse transcriptase Download PDF

Info

Publication number
WO2002070679A3
WO2002070679A3 PCT/NO2002/000069 NO0200069W WO02070679A3 WO 2002070679 A3 WO2002070679 A3 WO 2002070679A3 NO 0200069 W NO0200069 W NO 0200069W WO 02070679 A3 WO02070679 A3 WO 02070679A3
Authority
WO
WIPO (PCT)
Prior art keywords
derived
reverse transcriptase
peptide fragments
human telomerase
telomerase reverse
Prior art date
Application number
PCT/NO2002/000069
Other languages
French (fr)
Other versions
WO2002070679A2 (en
Inventor
Jon Amund Eriksen
Gustav Gaudernack
Mona Moeller
Original Assignee
Gemvax As
Jon Amund Eriksen
Gustav Gaudernack
Mona Moeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemvax As, Jon Amund Eriksen, Gustav Gaudernack, Mona Moeller filed Critical Gemvax As
Priority to AU2002233839A priority Critical patent/AU2002233839A1/en
Publication of WO2002070679A2 publication Critical patent/WO2002070679A2/en
Publication of WO2002070679A3 publication Critical patent/WO2002070679A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The polypeptide R E E I L A K F L H W L S V Y V V E L and variants/fragments thereof are particularly useful in producing anticancer vaccine for populations of individuals having varying HLA profiles. This polypeptide comprises a surprisingly large number of HLA class I and HLA class II epitopes in overlapping or nested form.
PCT/NO2002/000069 2001-03-02 2002-02-19 Peptide fragments, derived from human telomerase reverse transcriptase WO2002070679A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002233839A AU2002233839A1 (en) 2001-03-02 2002-02-19 Peptide fragments, derived from human telomerase reverse transcriptase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0105238.0A GB0105238D0 (en) 2001-03-02 2001-03-02 Vaccines
GB0105238.0 2001-03-02

Publications (2)

Publication Number Publication Date
WO2002070679A2 WO2002070679A2 (en) 2002-09-12
WO2002070679A3 true WO2002070679A3 (en) 2002-11-14

Family

ID=9909886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NO2002/000069 WO2002070679A2 (en) 2001-03-02 2002-02-19 Peptide fragments, derived from human telomerase reverse transcriptase

Country Status (3)

Country Link
AU (1) AU2002233839A1 (en)
GB (1) GB0105238D0 (en)
WO (1) WO2002070679A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2602453T3 (en) * 2008-06-16 2017-02-21 Mediolanum Farmaceutici S.P.A. Anti-tumor immunotherapy
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
EP2453243A1 (en) * 2010-11-11 2012-05-16 Cosmo S.p.A. Method for the diagnosis and/or follow up of the evolution of a tumor
WO2014079464A1 (en) * 2012-11-21 2014-05-30 Sherif Salah Abdul Aziz A novel enzymes compositions for treatment of human immunodeficiency virus (hiv) infection

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014756A1 (en) * 1991-02-26 1992-09-03 Norsk Hydro A.S Therapeutically useful peptides and peptides fragments
WO2000002581A1 (en) * 1998-07-08 2000-01-20 Norsk Hydro Asa Antigenic peptides derived from telomerase
WO2000025813A1 (en) * 1998-10-29 2000-05-11 Dana-Farber Cancer Institute CANCER IMMUNOTHERAPHY AND DIAGNOSIS USING UNIVERSAL TUMOR ASSOCIATED ANTIGENS, INCLUDING hTERT
US6093809A (en) * 1996-10-01 2000-07-25 University Technology Corporation Telomerase
WO2001060391A1 (en) * 2000-02-15 2001-08-23 Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014756A1 (en) * 1991-02-26 1992-09-03 Norsk Hydro A.S Therapeutically useful peptides and peptides fragments
US6093809A (en) * 1996-10-01 2000-07-25 University Technology Corporation Telomerase
WO2000002581A1 (en) * 1998-07-08 2000-01-20 Norsk Hydro Asa Antigenic peptides derived from telomerase
WO2000025813A1 (en) * 1998-10-29 2000-05-11 Dana-Farber Cancer Institute CANCER IMMUNOTHERAPHY AND DIAGNOSIS USING UNIVERSAL TUMOR ASSOCIATED ANTIGENS, INCLUDING hTERT
WO2001060391A1 (en) * 2000-02-15 2001-08-23 Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BORIS MINEV ET AL.: "Cytotoxic T cell immunity against telomerase reverse transcriptase in humans", PROC. NATL. ACAD. SCI. USA, vol. 97, no. 9, 2000, pages 4796 - 4801, XP002155017 *
MARIANNE K. GJERTSEN ET AL.: "Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12VAL) peptide vaccination of a patient, recognize 12VAL-dependent nedted epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation", INT. J. CANCER, vol. 72, 1997, pages 784 - 790, XP000882593 *
POUL BENNEKOU ET AL.: "Specific blockers of chloride conductance, NS1652 and NS3623, reduce sickle cell dehydration in vitro and in vivo", BLOOD, vol. 94, 1999, pages 677A, ABSTRACT 2998, XP002954589 *
ROBERT H. VONDERHEIDE ET AL.: "The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes", IMMUNITY, vol. 10, 1999, pages 673 - 679, XP000890114 *
SCHULTZE J.L. ET AL.: "Search for universal tumor antigens: potential of the catalytic telomerase subunit", BLOOD, vol. 92, 1998, pages 500A, ABSTRACT 2058, XP002954590 *

Also Published As

Publication number Publication date
WO2002070679A2 (en) 2002-09-12
AU2002233839A1 (en) 2002-09-19
GB0105238D0 (en) 2001-04-18

Similar Documents

Publication Publication Date Title
EP2394655A3 (en) Epitope sequences
WO2004022709A3 (en) Epitope sequences
WO2003022869A3 (en) Human immunodeficiency virus envelope clycoprotein mutants and uses thereof
EP2388271A3 (en) Human Antibodies and Proteins
WO2003038047A3 (en) Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
WO2002079232A3 (en) Reducing the immunogenicity of fusion proteins
WO1999010375A3 (en) Vaccine against hpv
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
WO2003028760A3 (en) Vaccine
WO2002074795A3 (en) Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
AU2003256912A8 (en) Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
WO2003087757A3 (en) Particle-bound human immunodeficiency virus envelope clycoproteins and related compositions and methods
WO2003003986A3 (en) Parathyroid hormone antibodies and related methods
WO2002070679A3 (en) Peptide fragments, derived from human telomerase reverse transcriptase
WO2002072627A8 (en) Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
AU2002255649A1 (en) Band 3 antigenic peptides, malaria polypeptides and uses thereof
AU2002228347A1 (en) Malaria plasmodium antigen polypeptide SE36, method of purifying the same and vaccine and diagnostic with the use of the thus obtained antigen
EP2277918A3 (en) Mhc class I and II peptide antigens derived from tumour antigen 5t4
WO2004058188A3 (en) Vaccine compositions and methods
WO2006007555A3 (en) Rotavirus antigens
MXPA04002103A (en) A caspase- 8 binding protein, its preparation and use.
AU2002303646A1 (en) Vectors having replication, immunogenicity and/or pathogenicity under stress promoter regulation and use thereof
AU2003300870A8 (en) Immunogenic mutant human immunodeficiency virus gp120 polypeptides, and methods of using same
EP1411964A4 (en) THE BLOOD GENERATING PEPTIDES AND THEIR USES
WO2002069691A3 (en) Immunogenic hiv peptides for use as reagents and vaccines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC (EPO FORM 1205A DATED 29.01.04)

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载